Advancing The Role Of The Sglt2 Inhibitors In The T2d Treatment Paradigm | Latest News RSS feed

Advancing The Role Of The Sglt2 Inhibitors In The T2d Treatment Paradigm - Latest News


SGLT2 inhibitors: an emerging option for cardiologists?

But Boehringer’s trial goes beyond improved CV outcomes for diabetes patients to consider its product’s role for ... the use of SGLT2 inhibitors for the treatment of heart failure patients without typ... read more

Poxel Announces Completion of Patient Enrollment for the TIMES 3 - wistv.com - Columbia, South Carolina

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor ... organs which play an im... read more

How The Global Pharma Industry Will Shape Up In The Next 5 Years?

The 39 novel drugs approved in FY 2012 includes groundbreaking treatment for a form of cystic fibrosis, the first human cord blood product ever approved, and the first drugs to treat advanced basal .. ... read more

Looking for another news?


Poxel Announces Completion of Patient Enrollment for the TIMES 3 - KFVS12 News & Weather Cape Girardeau, Carbondale, Poplar Bluff

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor ... organs which play an im... read more


Poxel Announces Completion of Patient Enrollment for the TIMES 3 - KFDA - NewsChannel 10 / Amarillo News, Weather, Sports

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor ... organs which play an im... read more

Poxel Announces Completion of Patient Enrollment for the TIMES 3 - KSWO 7News | Breaking News, Weather and Sports

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor ... organs which play an im... read more

Poxel Provides Business Update and Reports Results for Full Year 2017

In this study, Imeglimin will be administrated orally as a monotherapy or combination therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor ... Phase 1 and 2 programs. ... read more

AstraZeneca Presents New Data from Multiple Studies on the Effect of BYDUREON on Glucose Fluctuations in Patients with Type 2 Diabetes

1 ” Further exploratory analysis of BYDUREON and glucose fluctuations was provided in the poster “Effects of Exenatide Once Weekly on Dynamics of 24h Glucose Patterns in Patients with T2D ... treatmen... read more

Clinical Implications of Canagliflozin Treatment in Patients With Type 2 Diabetes

SGLT2 ... the role of the kidney in type 2 diabetes, describes the rationale for renal SGLT2 as a new target for glycemic control, and focuses on the clinical implications of incorporating the SGLT2 i... read more

New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes

The combination of these effects provides a differentiated drug profile and the opportunity for sotagliflozin to transform the treatment paradigm ... SGLT1 and SGLT2 inhibitor mechanism of action in d... read more

2017 Brands of the Year: 5 Impact Areas

The industry press has suggested that Jardiance’s rise could be slowed in the event of positive CV outcomes data for other SGLT2 inhibitor drugs ... Jardiance for the treatment of people, both with an... read more

New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 Diabetes

THE WOODLANDS, Texas, Sept. 13, 2017 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced that the New England Journal of Medicine (NEJM) ... an investigational dual SGLT1 and SGLT2 in... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us